Judge Profile
Helen Adams is a seasoned financial executive, CPA, and life science board member with over 35 years of leadership experience. A retired Deloitte partner and former Managing Partner for Haskell & White LLP,she currently serves as Lead Independent Director and Audit Committee Chair for Immix Biopharma (NASDAQ: IMMX). She is also on the board of Nexcella, Inc., and was recently Audit Committee Chair for Prometheus Biosciences, acquired by Merck for $11 billion. Active in San Diego’s business and philanthropic communities, Helen has heldleadership roles in numerous organizations, earned multiple awards, and is a mentor and speaker at leadership conferences. She holds a Bachelor of Science in Accounting from San Diego State University and completed an Executive Leadership program at Columbia University.